Dr. Maximilian Stahl: Precision AML Therapy | Ep. 13

In this episode of The Oncology Insights Podcast, Dr. Maximilian Stahl, Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center, explains how acute myeloid leukemia care is becoming more precise. He discusses molecular testing, induction therapy selection, targeted agents, transplant decisions, APL advances, and early phase trials for high-risk AML. Listen now on all major platforms!

"Molecular genetics now guide AML treatment selection, helping clinicians choose the best first therapy instead of simply starting the fastest regimen."

Meet the guest: Dr. Maximilian Stahl is Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center and Assistant Professor of Medicine at Yale School of Medicine. His work focuses on acute leukemia, early phase clinical trials, targeted therapy, measurable residual disease, and drug development for high-risk AML. Learn more from Dr. Maximilian Stahl on The Oncology Insights Podcast, available on all major platforms.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (01:47) Introduction
• (06:48) AML testing
• (12:03) Transplant choices
• (17:49) Maintenance therapy
• (23:27) MRD monitoring
• (29:51) GVHD advances
• (40:03) Closing thoughts

The Oncology Insights Podcast is trusted and supported by innovative companies like:

- Elevate

- WiseVAs

- ZentrixOS

- Zentrix Insights

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

YouTube: The Oncology Insights Podcast

Facebook: The Oncology Insights Podcast

TikTok: The Oncology Insights Podcast